BioVoice News June 2016 Issue 2 Volume 1 - Page 40

bio chat “ diagnostics in India. We work with hospitals and clinicians in the country to offer diagnostics services based on genomics. MedGenome offers pan- India sample collection, monitored by state-of-the-art management information systems, offering all technology platforms for sequencing and advanced analytics for high-end interpretation. All these in collaborations with hospitals, doctors within hospitals and specialty labs across the country. collaborations and future expansion is towards familiarising and creating awareness regarding genetic tests even to the remote corners of India. Our mission has always been to improve global health by developing deep insights into diseases at the genetic and molecular level. MedGenome aims to be a global player in genomics in the coming years. big step in educating their patients. Advances in bioinformatics have improved the quality of insights generated from the analysis of genomic data; but the flood of genomic information continues to challenge our existing analytical capabilities. Certain factors like regulatory body approval, and reimbursement from insurance companies may prove to be crucial in determining the growth of this industry. In the western world, insurers have started accepting genomic tests in their formulary as it is expected to reduce the cost of down-the-line treatment. In India, these tests are yet to be offered at affordable prices. There is also a great need for clinicians who have a good understanding of genomics and its clinical significance. The patient journey must be well managed so that if a particular condition is identified, the experts are brought in to handle the situation and help the individual. There is a dearth of genetic counsellors who can explain genomics findings to the affected individuals and their families. In addition to this, factors like lack of resources for effective data analysis, cost of technology, lack of baseline genomics data of Indian origin and unclear policies on intellectual property rights also pose hindrances to the industry. The patient journey must be well managed so that if a particular condition is identified, the experts are brought in to handle the situation and help the individual. There is a dearth of genetic counsellors who can explain genomics findings to the affected individuals and their families. For institutions with research focus, MedGenome partners to establish research and diagnostics centres pooling in the combined capabilities of both the institutions. Company invests in designing, building and maintaining such genomics centres within the partner institutions. These genomic centres at key locations across the country also facilitate the dissemination of scientific knowledge to the local population, while allowing them to avail of cost-effective genetic testing, an expensive option if availed of abroad. They also help in reduction of time for diagnosis and cost of treatment by enabling early diagnosis, and facilitating preventive measures like family screening. We have almost doubled in revenues in FY 2015 compared to last year. Our international collaborations have also seen fruit across various countries primarily because of the high quality and affordable testing that we offer in this region. What is the future outlook of the company including the short and long term plans? MedGenome is a pioneer in genomics-based diagnostics and research in India and we intend to expand our base by penetrating deep into the market. Our strategic 40 BioVoiceNews | June 2016 Expansion of our academic research collaboration is a focus. MedGenome is developing targeted collaborations with both Indian and international academic institutes and scientists, to whom our genomic research capacities, will be showcased. At a global level we plan to expand our genetic diagnostics and academic research collaboration in various geographies including Middle-East and South-East Asia, and in countries where there is a huge burden of genetic disorders. Experts say India has the potential to be the diagnostic capital of the world but there are challenges. How would you comment on this? The future of the industry is promising. However it brings with it a necessity for better data management and conversion to clinical application. Doctors and hospitals in India are also taking a Overall, genomics offers a plethora of opportunities that are yet to be seized. The greatest benefit that can come from the application of genomics to human health care is to provide prescribers and individuals with useful insights into their genotype which will enable them to take preventive/curative steps for their disease management.